HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Photodynamic therapy in patients with recurrent gynecologic cancers].

Abstract
Patients with recurrent gynaecological carcinomas have a poor prognosis, with a survival of a few months. Three patients with a recurrent vulva carcinoma, one patient with a recurrent cervical carcinoma, one patient with a recurrent endometrial carcinoma, and one patient with a recurrent breast carcinoma underwent PDT after parenteral or topical sensitisation with Photosan 3. From these patients, two of them showed a complete response with no evidence of disease for 32 and 29 months. One patient responded partially with two recurrences, which were treated twice after tropical sensitisation, living now 21 months. The remaining three patients showed partial response and died 3 to 8 months after PDT. The energy applied was derived from an argon-dye-laser ranging between 225 and 750 joule/cm2. Photosan 3 was given intravenously at a dose of 2.5 mg/kg body weight and was tolerated without any allergic reaction. The response rate in three of six patients in recurrent gynaecological malignancies encourages us to pursue PDT in gynaecological disease.
AuthorsH Hetzel, E Müller-Holzner, C Marth, H Kostron
JournalGeburtshilfe und Frauenheilkunde (Geburtshilfe Frauenheilkd) Vol. 53 Issue 5 Pg. 333-6 (May 1993) ISSN: 0016-5751 [Print] Germany
Vernacular TitlePhotodynamische Therapie bei Patientinnen mit Rezidiven gynäkologischer Karzinome.
PMID8514105 (Publication Type: English Abstract, Journal Article)
Topics
  • Aged
  • Aged, 80 and over
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Genital Neoplasms, Female (drug therapy, pathology, surgery)
  • Hematoporphyrin Photoradiation
  • Humans
  • Middle Aged
  • Neoplasm Staging

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: